- Home
- underscore plus
- ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer
4.8 (415) · $ 21.50 · In stock
Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti
ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus
ASCO GU 2022: Real-World Treatment Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
PDF) Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
Elizabeth Plimack Fox Chase Cancer Center - Philadelphia PA
ASCO 2021: Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from 42-Month Follow-up of KEYNOTE-426
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
Frontiers Role of metastasectomy in the management of renal cell carcinoma
ASCO GU 2018: Safety and Efficacy of Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer
ASCO GU 2022: Real-World Treatment Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
PDF) Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome
PDF) Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome
ASCO 2021: Pembrolizumab Versus Placebo as Post-Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Randomized, Double-Blind, Phase III KEYNOTE-564 Study
PDF) The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer
